Ayurveda’s next phase is being built on infrastructure
Feb - June 2026
Welcome to Ayurveda Post, the February–May 2026 edition from CAYEIT.
These four months show a decisive shift in the global Ayurveda and medicinal-herbs landscape. The conversation is no longer limited to heritage, wellness, or revival. It is moving toward infrastructure: evidence centres, pharmacopoeial standards, medicinal-plant supply chains, regulatory training, export readiness, and digitally enabled knowledge systems.
One message stands out clearly: Ayurveda’s next phase will be shaped by those who can connect classical wisdom with measurable quality, conservation, safety, research, and market credibility. The strongest institutions will be those that protect medicinal-plant diversity, generate reliable evidence, train competent professionals, and build globally trusted products.
The opportunity is enormous -but it comes with responsibility. Global acceptance will not be earned through emotional claims alone. It will be earned through documented safety, reproducible formulations, ethical sourcing, clinical reasoning, transparent labelling, and research designs that modern health systems can understand.
— Chief Editor
GLOBAL POLICY & KNOWLEDGE INFRASTRUCTURE
WHO strengthens the evidence agenda for traditional & integrative medicine
In February 2026, the WHO designated the Charité Competence Center for Traditional and Integrative Medicine in Berlin as a WHO Collaborating Centre for Traditional, Integrative, and Preventive Medicine. This directly supports the WHO Global Traditional Medicine Centre’s agenda of building stronger evidence, health-system integration, real-world evidence, policy research, and global knowledge exchange.
Why it matters: Traditional medicine is now discussed through the language of clinical research, health-system integration, implementation frameworks, and global policy dialogue. Ayurveda institutions, universities, and research groups must prepare for this evidence-oriented environment by strengthening documentation, outcome measurement, interdisciplinary research, and international collaboration.
Source: WHO · Collaborating-centre announcement ↗
MEDICINAL PLANTS & BIODIVERSITY
NMPB marks 25 years and outlines a roadmap for medicinal plants
On 11 February 2026, the National Medicinal Plants Board organized a Chintan Shivir on Medicinal Plants in New Delhi, marking 25 years of NMPB. It brought together policymakers, experts, industry leaders, and state representatives to discuss sustainable growth, innovation, value-chain strengthening, and India’s global leadership in medicinal plants.
This is not only an agricultural story - it is an Ayurveda infrastructure story. The quality of Ayurveda begins long before the medicine reaches the pharmacy: authentic raw material, correct botanical identification, sustainable cultivation, post-harvest handling, storage, testing, and traceability.
Why it matters: A strong medicinal-plants sector is essential for credible Ayurveda - there is no quality finished product without a quality starting material.
Source: PIB · NMPB Chintan Shivir (PRID 2226284) ↗
World Wildlife Day 2026 puts medicinal & aromatic plants at the centre
World Wildlife Day 2026 was observed on 3 March with the theme “Medicinal and Aromatic Plants: Conserving Health, Heritage and Livelihoods.” It highlighted plants used in traditional medicine, cultural heritage, biodiversity, and rural livelihoods.
The message is powerful: medicinal plants are not only raw materials-they are living biodiversity assets. India’s medicinal-plant wealth, including thousands of species used in Indian systems of medicine and folk traditions, must be conserved through in-situ and ex-situ strategies, quality planting material, community participation, and sustainable trade.
Why it matters: Conservation is now a professional responsibility. Without it there is no long-term drug security, no ethical sourcing, and no credible global supply chain.
Source: PIB · World Wildlife Day 2026 (PRID 2234951) ↗
AYUSH ACCESS & PUBLIC HEALTH
National Arogya Fair 2026 links preventive healthcare with medicinal farming
The National Arogya Fair 2026 placed Ayush systems before the public through consultations, health check-ups, medicines, exhibitions, yoga demonstrations, expert sessions, and industry participation. A key feature was the focus on “Ayurvedic Farming: Production, Value Addition and Marketing,” covering medicinal-plant cultivation, agroforestry, post-harvest management, and market linkages.
Why it matters: Public health, farmer livelihoods, cultivation, product quality, and consumer education can connect in one ecosystem. Ayurveda’s growth depends not only on clinics and products, but on the farmers, collectors, processors, regulators, and educators behind the system.
Source: PIB · National Arogya Fair 2026 (PRID 2232271) ↗
Five Ayurvedic products enter the Jan Aushadhi basket
In March 2026, the Government of India added five Ayurvedic products under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana product basket: Chyawanprash Special, Triphala, Shilajit, and Ashwagandha products — bringing selected formulations into an affordability-oriented public-access framework.
Why it matters: Affordability must move together with quality assurance, appropriate use, and consumer education. As products become more widely available, correct indications, safe use, contraindication awareness, and pharmacovigilance become even more important.
Source: PIB · Jan Aushadhi basket update (PRID 2246064) ↗
REGULATION, QUALITY & MARKET ACCESS
India emphasizes pharmacopoeial standards & quality control for Ayush
On 18 March 2026, the Ministry of Ayush highlighted the role of the Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H) in laying down formulary specifications and pharmacopoeial standards for Ayurveda, Siddha, Unani, and Homoeopathy drugs — defining identity, purity, strength, and quality requirements for ASU&H medicines.
Why it matters: In international markets, tradition is not enough. Products must demonstrate quality through recognized standards, validated methods, raw-material authentication, contaminant control, and batch consistency. Pharmacopoeial discipline is the bridge between classical formulation knowledge and modern regulatory confidence.
Source: PIB · Pharmacopoeial standards (PRID 2241692) ↗
PCIM&H trains regulators & quality-control stakeholders
From 18–22 May 2026, PCIM&H organized a five-day capacity-building training programme for drug-enforcement officers, quality-control personnel, manufacturers, researchers, and other ASU&H stakeholders - covering regulatory knowledge, technical competence, pharmacognostic identification, phytochemical analysis, GMP, and hands-on laboratory training.
Why it matters: A system cannot scale safely if its regulators, manufacturers, researchers, and educators don’t share a common technical language. Strengthening regulatory competence is a patient-safety and market-trust intervention, not mere administration.
Source: PIB · PCIM&H training programme (PRID 2264306) ↗
Europe continues structured herbal-medicine assessment through EMA HMPC
The EMA continued its Committee on Herbal Medicinal Products (HMPC) work through March and May 2026 meetings - agendas, minutes, and reports related to EU herbal monographs, guidelines, and herbal-medicine assessment.
Why it matters: EMA’s HMPC is a key global reference point. Europe’s framework shows how traditional use, safety data, quality requirements, monographs, and claim boundaries are organized. Ayurveda products seeking global acceptance should learn from it: define the category clearly, support claims responsibly, document safety, and maintain quality consistency.
Source: EMA · Committee on Herbal Medicinal Products (HMPC) ↗
Safety warning from the US: heavy metals remain a global credibility risk
The U.S. FDA continues to warn consumers about heavy-metal poisoning risks associated with certain unapproved Ayurvedic drug products, noting that some may contain lead, mercury, arsenic, and other metals, with potential for serious health effects.
Why it matters: The strongest response is not defensiveness but quality leadership - authenticated raw materials, tested batches, transparent labelling, contaminant limits, responsible rasaushadhi use, practitioner education, consumer guidance, and active adverse-event reporting.
Source: FDA · Heavy-metal poisoning warning ↗
RESEARCH & EVIDENCE
Ayurgyan Scheme supports Ayurveda research & scientific infrastructure
In March 2026, the Ministry of Ayush highlighted that the Ayurgyan Scheme is supporting Ayurveda research through 16 R&D projects and expanded scientific infrastructure - part of a broader push to strengthen research capacity.
Why it matters: Ayurveda research needs an ecosystem, not isolated studies - trained researchers, well-defined protocols, classical-textual grounding, pharmacognosy, drug standardization, clinical research, data systems, ethics review, and publication support.
Source: PIB · Ayurgyan Scheme (PRID 2241124) ↗
Cardiology: Pushkar Guggulu & Haritaki enter a double-blind RCT protocol
A PubMed-indexed protocol describes a double-blind randomized controlled study evaluating Ayurveda interventions - Pushkar Guggulu and Haritaki - as adjuncts to standard care in stable coronary artery disease.
Why it matters: Cardiovascular disease is a high-burden global area, and Ayurveda’s contribution must be evaluated with suitable safety monitoring, defined endpoints, and transparent design. Protocol publications make methods visible before results, improving research accountability.
Source: PubMed · CAD trial protocol (41580651) ↗
Neuro-Ayurveda advances through a Nasya & fMRI protocol
A 2026 PubMed-indexed protocol examines the impact of intranasal administration (Nasya) of Ayurveda medicine in apparently healthy individuals using neurophysiological variables and functional connectivity via fMRI.
Why it matters: This is a mechanism-oriented direction -not only asking whether an intervention works, but how it may act and what measurable physiological changes it may produce. Such studies must avoid overclaiming, but can bridge Ayurveda and neuroscience.
Source: PubMed · Nasya & fMRI protocol (41511827) ↗
Computational Ayurveda: knowledge graphs & network pharmacology
A 2026 preprint investigates Ayurvedic single herbal drugs for diabetes and obesity using knowledge graphs, pathway analysis, and network pharmacology - curating herbs, phytochemicals, targets, disease genes, and FDA-approved drug information to explore multi-target mechanisms.
Why it matters: Classical Ayurveda understands drugs through rasa, guna, virya, vipaka, prabhava, karma, and clinical context. Computational approaches add another layer - phytochemicals, targets, pathways, networks. The next frontier is not replacing Ayurveda with AI, but building intelligent bridges between classical pharmacology and systems biology.
Source: arXiv · Computational Ayurveda preprint (2601.21643) ↗
GLOBAL MARKET & EXPORT READINESS
AYUSHEXCIL & Spices Board partnership promotes “Spice and Heal”
On 25 May 2026, AYUSHEXCIL and the Spices Board of India signed an MoU to strengthen the global promotion of Ayush products and medicinal spices — described as a step to support farmers, MSMEs, startups, exporters, and India’s natural-wellness leadership.
Why it matters: Many medicinal herbs also live in the food, spice, nutraceutical, and wellness economy. Turmeric, ginger, ashwagandha, triphala ingredients, and others must be positioned responsibly. Export growth depends on quality documentation, claim discipline, residue testing, contaminant control, traceability, and globally acceptable communication.
Source: PIB · AYUSHEXCIL–Spices Board MoU (PRID 2265130) ↗
DIGITAL HEALTH & AI
Ayush Pavilion at India-AI Impact Summit highlights citizen-centric AI
In February 2026, the Ministry of Ayush showcased citizen-centric AI innovations focused on holistic health and wellbeing at the India-AI Impact Summit — reflecting the growing intersection between Ayush, digital public health, and artificial intelligence.
Why it matters: AI can support education, clinical documentation, decision-support, pharmacovigilance, drug research, manuscript digitization, personalized wellness, and public-health communication. But digital Ayurveda must be evidence-aware, transparent, safe, explainable, and clinically responsible — deepening Ayurveda’s integrity, not diluting it into generic wellness content.
Source: PIB · Ayush Pavilion, India-AI Summit (PRID 2229381) ↗
EDITORIAL VIEW
From isolated excellence to organized systems
February to May 2026 gives Ayurveda a clear direction: the future belongs to evidence-ready, safety-conscious, biodiversity-respecting, digitally capable, and globally literate Ayurveda.
The sector must now move from isolated excellence to organized systems. Medicinal plants need conservation and supply-chain intelligence. Products need pharmacopoeial discipline and contaminant control. Practitioners need competency-based training. Researchers need robust protocols. Digital innovators need safety and evidence governance. Exporters need quality documentation and responsible claims.
Ayurveda’s greatest strength is its deep civilizational wisdom. But its global future will depend on how well that wisdom is translated into standards, systems, science, and service.
CAYEIT helps translate Ayurveda’s classical foundations into globally legible systems: reproducible quality frameworks, evidence-first research pathways, responsible digital innovation, and safety-centered governance. We support practitioners, educators, researchers, and innovators with tools, standards, and training that enable Ayurveda to scale with credibility.
We welcome your inputs and suggestions. contact@cayeit.com
Ayurveda Post - Editorial Team
So excited to read that, thank you 🙏🥳